Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jesse Romeu Velez

Pulmonary Disease Winter Haven, FL Medical Doctor

NPI 1215918420 CMS profile 99837

500 E Central Ave, Winter Haven, FL 33880

Open in the dashboard

General payments

$15,673

659 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jesse Romeu Velez of Winter Haven, FL is reported in the CMS Open Payments database as having received $15,673 across 659 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,885 103
2024 General $2,214 89
2023 General $2,238 92
2022 General $1,664 80
2021 General $2,048 92
2020 General $1,837 86
2019 General $2,787 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jesse Romeu Velez
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jesse Romeu Velez were reported at $2,885. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jesse Romeu Velez Pulmonary Disease median Middle half National median
2019 $2,787 $377 $109–$1,340 $163
2020 $1,837 $230 $56–$907 $114
2021 $2,048 $269 $68–$1,072 $132
2022 $1,664 $390 $100–$1,457 $149
2023 $2,238 $419 $114–$1,659 $160
2024 $2,214 $476 $123–$1,818 $164
2025 $2,885 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $3,460 168 payments
  2. AstraZeneca Pharmaceuticals LP $2,475 109 payments
  3. Actelion Pharmaceuticals US, Inc. $1,955 71 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,237 61 payments
  5. Merck Sharp & Dohme Corporation $858 41 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $818 22 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $682 28 payments
  8. Regeneron Healthcare Solutions, Inc. $428 16 payments
  9. Grifols USA, LLC $374 21 payments
  10. Genzyme Corporation $282 11 payments
  11. Other $3,105 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,857 650 payments
  2. Consulting Fee $525 3 payments
  3. Education $291 6 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $2,251 109 payments
  2. OPSUMIT $1,736 68 payments
  3. BREZTRI $891 27 payments
  4. UPTRAVI $857 19 payments
  5. Adempas $818 22 payments
  6. FASENRA $756 27 payments
  7. GLASSIA $688 28 payments
  8. BELSOMRA $563 30 payments
  9. AIRSUPRA $486 16 payments
  10. NUCALA $453 32 payments
  11. Other $8,736 357 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

7,724

Median for Pulmonary Disease: 936

Drug cost

$6,084,609

Median for Pulmonary Disease: $487,987

Branded share of claims

52.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Adempas Riociguat Brand 153 $2,045,118
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 1,035 $1,178,270
Opsumit Macitentan Brand 49 $617,457
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 368 $412,725
Orenitram Er Treprostinil Diolamine Brand 24 $320,757
Ofev Nintedanib Esylate Brand 18 $238,566
Spiriva Respimat Tiotropium Bromide Brand 156 $187,641
Breo Ellipta Fluticasone/Vilanterol Brand 219 $167,928
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 168 $165,150
Xolair Omalizumab Brand 48 $152,167

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$125,911

Medicare's payments for the services billed

Medicare patients

673

Average age 77

Services billed

2,572

373 women, 300 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 59%
Arthritis 59%
COPD 57%
Ischemic heart disease 46%
Diabetes 39%
Depression 30%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$270 1,035 —
DUPIXENT
$263 — —
Adempas
$241 153 —
GLASSIA
$187 — —
AIRSUPRA
$169 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

659 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record